The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ENVX, IVVD and RVYL

ACCESSWIRE 8-Feb-2023 9:46 AM

NEW YORK, NY / ACCESSWIRE / February 8, 2023 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Enovix Corporation (NASDAQ:ENVX)

This lawsuit is on behalf of all investors who purchased or otherwise acquired Enovix common stock (or Rodgers Silicon Valley Acquisition Corp. common stock prior to July 15, 2021) between February 22, 2021 and January 3, 2023, inclusive.

A class action has commenced on behalf of certain shareholders in Enovix Corporation. According to the lawsuit, the Company made false and misleading statements to the market. Specifically, Enovix overstated its ability to produce batteries at commercial scale. Despite touting its "meaningful progress" in developing its manufacturing capabilities, Enovix continued to face serious production problems. Based on these facts, the Company's public statements were false and materially misleading throughout the class period.

Shareholders may find more information at https://securitiesclasslaw.com/securities/enovix-class-action-submission-form/?id=36363&from=1

Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD)

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.

A class action has commenced on behalf of certain shareholders in Invivyd, Inc f/k/a Adagio Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

Shareholders may find more information at https://securitiesclasslaw.com/securities/invivyd-inc-f-k-a-adagio-therapeutics-inc-loss-submission-form/?id=36363&from=1

Ryvyl Inc. f/k/a GreenBox POS (NASDAQ:RVYL)

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ryvyl securities: (1) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's January 29, 2021 public offering; and/or (2) between January 29, 2021 and January 20, 2023, inclusive.

A class action has commenced on behalf of certain shareholders in Ryvyl Inc f/k/a GreenBox POS. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Ryvyl downplayed serious issues with its internal controls; (2) Ryvyl's financial statements for December 31, 2021 through and including interim periods ended September 30, June 30, and March 31, 2022 contained errors resulting in overstatements of revenue, assets, and stockholders' equity and understatements of losses; (3) as a result, Ryvyl would need to restate its previously issued financial statements for those periods; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/ryvyl-inc-f-k-a-greenbox-pos-loss-submission-form/?id=36363&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm